KN-PEPTIDE
Well-known member
Administration is subcutaneous injection once weekly, on the same day each week. Rotate injection sites among abdomen, outer thigh and upper arm. Do not reuse needles.
Standard dose escalation schedule: For the first 4 weeks, take 2.5 mg per week. From week 5 to week 8, take 5 mg per week. From week 9 to week 12, take 7.5 mg per week. Starting from week 13 and onward, the maintenance target dose is 10 mg weekly. Only increase your dose if you tolerate the current dose well. Hold dose escalation if you have persistent gastrointestinal discomfort.
If you miss a dose: if you are no more than 5 days late, take the dose as soon as possible. If you are more than 5 days late, skip this missed dose and resume your regular schedule on the next planned injection day. Do NOT double your dose to make up for the missed one.
The most frequently reported side effects are gastrointestinal symptoms, which mostly happen during dose escalation and typically become milder as tolerance develops over time. Common systemic symptoms include nausea, vomiting, diarrhea, constipation, bloating, reduced appetite, abdominal discomfort and fatigue. Less common systemic reactions are dizziness and hypoglycemia; the risk of low blood sugar rises notably if it is used together with insulin or sulfonylurea medications.
Typical injection site reactions consist of redness, itching, tenderness, local swelling, minor bruising or small hard lumps at the injection area. You should rotate your injection sites every time to reduce the chance of continuous local irritation.
You must stop administration right away and seek immediate medical help once you experience severe persistent abdominal pain, allergic reactions such as swelling on your face, lips or throat, breathing difficulty, severe vomiting that causes dehydration, or severe hypoglycemia.
This compound is contraindicated for anyone with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, previous pancreatitis. It is not suitable for pregnant or breastfeeding people. Do not use it together with semaglutide, retatrutide or other GLP‑1 / GIP agonists.
Standard dose escalation schedule: For the first 4 weeks, take 2.5 mg per week. From week 5 to week 8, take 5 mg per week. From week 9 to week 12, take 7.5 mg per week. Starting from week 13 and onward, the maintenance target dose is 10 mg weekly. Only increase your dose if you tolerate the current dose well. Hold dose escalation if you have persistent gastrointestinal discomfort.
If you miss a dose: if you are no more than 5 days late, take the dose as soon as possible. If you are more than 5 days late, skip this missed dose and resume your regular schedule on the next planned injection day. Do NOT double your dose to make up for the missed one.
The most frequently reported side effects are gastrointestinal symptoms, which mostly happen during dose escalation and typically become milder as tolerance develops over time. Common systemic symptoms include nausea, vomiting, diarrhea, constipation, bloating, reduced appetite, abdominal discomfort and fatigue. Less common systemic reactions are dizziness and hypoglycemia; the risk of low blood sugar rises notably if it is used together with insulin or sulfonylurea medications.
Typical injection site reactions consist of redness, itching, tenderness, local swelling, minor bruising or small hard lumps at the injection area. You should rotate your injection sites every time to reduce the chance of continuous local irritation.
You must stop administration right away and seek immediate medical help once you experience severe persistent abdominal pain, allergic reactions such as swelling on your face, lips or throat, breathing difficulty, severe vomiting that causes dehydration, or severe hypoglycemia.
This compound is contraindicated for anyone with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, previous pancreatitis. It is not suitable for pregnant or breastfeeding people. Do not use it together with semaglutide, retatrutide or other GLP‑1 / GIP agonists.